Mathew M.

• Partner with small to mid-sized businesses and startups across industries to provide high-level financial strategy that enables companies to scale and stabilize cash flow.
• Act as a trusted advisor to owners and leadership teams, helping them navigate critical moments of growth, transition, and stabilization.
• Created accurate forecasts that enabled a startup to close a critical round of funding.
• Advised a biotech founder pivoting to launch a new cutting-edge business, supporting team assembly and establishing the finance structure.
• Guided companies through ownership transitions by securing financing, developing forecasts, negotiating terms, and stabilizing cash flow.
• Partnered with leadership to create a succession plan for a fourth-generation industrial company and supported valuation and negotiation of terms.
• Negotiated with lenders to facilitate a management buyout, improving stability for an industrial asphalt and concrete company.
• Secured an SBA loan and renegotiated a line of credit to improve cash flow and enable the company president to buy out the founder.

ImmunoScape is transforming cancer therapy with its novel Seed-and-Boost approach, which combines our proprietary optimised TCR T cells with clinically-validated Immuno-STAT T cell engagers. This pioneering approach addresses the shortcomings of current cell therapies by enabling potent in vivo expansion of infused tumor targeting T-cells. Our combination therapy has the potential to transform cell therapy, through the delivery of safe, tolerable and effective therapies against cancer while simplifying the patient journey. We are currently advancing IND-enabling studies and accelerating entry into the clinic.

• Recruited by Singapore leadership to launch and run ImmunoScape’s U.S. division covering operations and financial operations.
• Established accounting systems, managed treasury functions, and built budgets and forecasts to support U.S. expansion.
• Led setup of the San Diego laboratory, negotiating the lease, recruiting scientists, and investing $2M in instruments and infrastructure.
• Collaborated with the board and investors to deliver actionable financial reporting and strategic alignment.
• Pitched to venture capital firms and helped close a $25M Series B funding round.
• Refined financial reporting and forecasting to enhance decision making and transparency.
• Mitigated a potential financial disaster by establishing processes and passing audits, enabling further funding rounds.
• Created and ran all U.S. operations including business development, sales, marketing, HR, finance, fundraising, and investor relations.
• Selected an external accounting firm to oversee forecasting, financing, banking, and taxes.
• Cultivated a high-performing team culture with near-zero turnover.

Henry Ford Health is a leading health care and medical services provider in the Southwest Detroit region.

• Established the finance function for a $350M EMR implementation, the largest investment in the hospital's history.
• Developed the business case demonstrating ROI for the EMR implementation, which became a benchmark for other health systems.
• Managed a $100M budget overseeing operational and capital expenditures with precision and transparency.
• Managed budgeting for the $350M EMR system, with the implementation used as a case study by other U.S. health systems.
• Reassembled governance structures for post go-live operations and established a system-wide IT steering committee.
• Drafted multiple business cases for post-implementation projects to enhance EMR functionality hospital-wide.
• Architected and launched a project and resource management system for a 200-person team to prioritize hundreds of projects.

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees.

• Launched and managed investment projects to expand the Asian market after organizing commercialization of a $250M product portfolio.
• Led cross-functional teams to drive business development, improve profitability, and negotiate high-value partnerships.
• Improved working capital and simplified the budget by streamlining processes across markets.
• Negotiated three new deals totaling $30M while managing a $40M portfolio of projects.
• Developed and presented business cases that supported expansion strategies, new product launches, and supply chain improvements.

• Created an alliance management function to improve profitability of strategic partnerships.
• Managed a $40M portfolio of strategic partner relationships across Asia.
• Improved profitability by exiting unprofitable products and identifying new high-growth products.
• Expanded alliance partnerships by negotiating three deals worth $30M in six months.
• Launched an alliance management system across 13 offices and 10 major partners to streamline operations.
• Reduced costs by centralizing supply chain and regulatory activities, saving several million dollars.
• Increased working capital by renegotiating unfavorable contract terms with two key partners.

• Launched a boutique management consulting practice in Asia serving life science and pharma clients and opened offices in the U.S. and Japan.
• Created Woodward Partners, a non-profit research institute to build collaborations with faculty and access relevant research for clients.
• Partnered with a European pharmaceutical client as strategic planning director to secure a $50M investment in Asia.
• Led market entry for a U.S. life-science instrument manufacturer into China and India with detailed business cases and board buy-in.
• Recruited a global advisory team of industry executives and senior university faculty to support client projects.